1
|
Kim KM, Ahn AR, Park HS, Jang KY, Moon WS, Kang MJ, Ha GW, Lee MR, Chung MJ. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer. BMC Cancer 2022; 22:940. [PMID: 36045334 PMCID: PMC9434900 DOI: 10.1186/s12885-022-10039-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 08/25/2022] [Indexed: 02/08/2023] Open
Abstract
AbstractIn human colorectal cancer (CRC), TP53 is one of the most important driver genes. Immunohistochemistry (IHC) has been used most often to assess the variational status of TP53. Recently, next-generation sequencing (NGS) of the TP53 gene has increased. However, to our knowledge, a comparison between TP53 status evaluated by IHC and NGS has not been studied. Therefore, the primary aim of this study was to compare the clinical effect of TP53 status evaluated by IHC and NGS in patients with CRC. The secondary aim was to investigate the correlation between expression of p53 by IHC and variational status of TP53 by NGS. We performed immunohistochemical staining of p53 and sequencing of TP53 by NGS in 204 human samples of CRC. We then analyzed the correlation between variational status of TP53 and p53 expression, along with their prognostic impact in CRC patients. There was significant correlation between p53 expression and TP53 variation, TP53 variation and higher N stage, and positive p53 expression and higher N stage. Positive IHC expression of p53 was significantly associated with overall survival (OS) of CRC patients by univariate analysis and was revealed as an independent prognostic factor by multivariate analysis. Additionally, the nonsense/frameshift p53 expression pattern showed a significantly better prognosis than the wild type and missense p53 expression patterns. However, the variational status of TP53 was not significant in OS of CRC patients. These results suggest that IHC expression of p53 protein correlates with variation status of TP53 and expression of p53 protein rather than variation status of TP53 has more significant impact on the OS of CRC patients.
Collapse
|
2
|
Ahn AR, Noh SJ, Hussein UK, Park HS, Chung MJ, Lee H, Moon WS, Kang MJ, Kim HJ, Lee NR, Jang KY, Kim KM. FAM83H and Nectin1 expression are related with survival and relapse of bladder urothelial carcinoma patients. BMC Urol 2021; 21:143. [PMID: 34625065 PMCID: PMC8501681 DOI: 10.1186/s12894-021-00908-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Accepted: 09/28/2021] [Indexed: 12/09/2022] Open
Abstract
Background FAM83H was originally reported to be essential for dental enamel formation. However, FAM83H has recently been implicated in tumorigenesis and tumor progression. Analysis of a publicly available gene expression database revealed a significant correlation between FAM83H and Nectin1 mRNA expression and bladder urothelial carcinoma (BUC). Therefore, we investigated the association between FAM83H and Nectin1 expression levels and the survival and recurrence of BUC in BUC patients using a tissue microarray. Methods We performed immunohistochemical staining of FAM83H and Nectin1 in 165 human BUC tissue sections, and analyzed the prognostic significance of FAM83H and Nectin1 expression. Results Both FAM83H and Nectin1 were mainly expressed in the cytoplasm, and their expression was significantly associated. FAM83H expression was significantly correlated with higher histologic grade, higher T stage, higher TNM stage, and recurrence. Nectin1 expression was significantly associated with higher histologic grade and recurrence. Univariate analysis showed FAM83H expression and Nectin1 expression were significantly associated with worse overall survival (OS) and shorter relapse-free survival (RFS) of BUC patients. In multivariate analysis, levels of FAM83H and Nectin1 were independent indicators of shorter survival of BUC patients. Conclusions Our results suggest that FAM83H and Nectin1 are important in the progression of BUC, and that expression patterns of these two proteins can be used as prognostic indicators of survival in BUC patients. Supplementary Information The online version contains supplementary material available at 10.1186/s12894-021-00908-2.
Collapse
Affiliation(s)
- Ae-Ri Ahn
- Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Sang Jae Noh
- Department of Forensic Medicine, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Usama Khamis Hussein
- Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea.,Faculty of Science, Beni-Suef University, Beni-Suef, Egypt
| | - Ho Sung Park
- Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Myoung Ja Chung
- Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Ho Lee
- Department of Forensic Medicine, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Woo Sung Moon
- Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Myoung Jae Kang
- Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Hyung Jin Kim
- Department of Urology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Na Ri Lee
- Department of Internal Medicine, Jeonbuk National University Hospital-Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Kyu Yun Jang
- Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
| | - Kyoung Min Kim
- Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea. .,Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.
| |
Collapse
|
3
|
Hussein UK, Ahmed AG, Song Y, Kim KM, Moon YJ, Ahn AR, Park HS, Ahn SJ, Park SH, Kim JR, Jang KY. CK2α/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway. Cells 2021; 10:cells10071770. [PMID: 34359939 PMCID: PMC8303481 DOI: 10.3390/cells10071770] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Revised: 07/09/2021] [Accepted: 07/11/2021] [Indexed: 12/28/2022] Open
Abstract
CK2α/CSNK2A1 is involved in cancer progression by phosphorylating various signaling molecules. Considering the role of CSNK2A1 in cancer progression and the phosphorylation of SIRT6 and the role of SIRT6 in chemoresistance through the DNA damage repair pathway, CSNK2A1 and SIRT6 might be involved in resistance to conventional anti-cancer therapies. We evaluated the expression of CSNK2A1 and phosphorylated SIRT6 in the 37 osteosarcoma patients and investigated the effects of CSNK2A1 and the phosphorylation of SIRT6 on Ser338 on resistance to the anti-cancer effects of doxorubicin. Higher expression of CSNK2A1 and phosphorylated SIRT6 was associated with shorter survival in osteosarcoma patients. U2OS and KHOS/NP osteosarcoma cells with induced overexpression of CSNK2A1 were resistant to the cytotoxic effects of doxorubicin, and the knock-down of CSNK2A1 potentiated the cytotoxic effects of doxorubicin. CSNK2A1 overexpression-mediated resistance to doxorubicin was associated with SIRT6 phosphorylation and the induction of the DNA damage repair pathway molecules. CSNK2A1- and SIRT6-mediated resistance to doxorubicin in vivo was attenuated via mutation of SIRT6 at the Ser338 phosphorylation site. Emodin, a CSNK2A1 inhibitor, potentiated the cytotoxic effects of doxorubicin in osteosarcoma cells. This study suggests that blocking the CSNK2A1-SIRT6-DNA damage repair pathway might be a new therapeutic stratagem for osteosarcomas.
Collapse
Affiliation(s)
- Usama Khamis Hussein
- Department of Pathology, Jeonbuk National University Medical School, Jeonju 54896, Korea; (U.K.H.); (A.G.A.); (K.M.K.); (A.-R.A.); (H.S.P.)
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Korea;
- Faculty of Science, Beni-Suef University, Beni-Suef 62511, Egypt
| | - Asmaa Gamal Ahmed
- Department of Pathology, Jeonbuk National University Medical School, Jeonju 54896, Korea; (U.K.H.); (A.G.A.); (K.M.K.); (A.-R.A.); (H.S.P.)
- Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef 62511, Egypt
| | - Yiping Song
- Department of Orthopedic Surgery, Jeonbuk National University Medical School, Jeonju 54896, Korea;
| | - Kyoung Min Kim
- Department of Pathology, Jeonbuk National University Medical School, Jeonju 54896, Korea; (U.K.H.); (A.G.A.); (K.M.K.); (A.-R.A.); (H.S.P.)
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Korea;
| | - Young Jae Moon
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Korea;
- Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, Jeonju 54896, Korea;
| | - Ae-Ri Ahn
- Department of Pathology, Jeonbuk National University Medical School, Jeonju 54896, Korea; (U.K.H.); (A.G.A.); (K.M.K.); (A.-R.A.); (H.S.P.)
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Korea;
| | - Ho Sung Park
- Department of Pathology, Jeonbuk National University Medical School, Jeonju 54896, Korea; (U.K.H.); (A.G.A.); (K.M.K.); (A.-R.A.); (H.S.P.)
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Korea;
| | - Su Jin Ahn
- Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, Jeonju 54896, Korea;
| | - See-Hyoung Park
- Department of Bio and Chemical Engineering, Hongik University, Sejong 30016, Korea
- Correspondence: (S.-H.P.); (J.R.K.); (K.Y.J.)
| | - Jung Ryul Kim
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Korea;
- Department of Orthopedic Surgery, Jeonbuk National University Medical School, Jeonju 54896, Korea;
- Correspondence: (S.-H.P.); (J.R.K.); (K.Y.J.)
| | - Kyu Yun Jang
- Department of Pathology, Jeonbuk National University Medical School, Jeonju 54896, Korea; (U.K.H.); (A.G.A.); (K.M.K.); (A.-R.A.); (H.S.P.)
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Korea;
- Correspondence: (S.-H.P.); (J.R.K.); (K.Y.J.)
| |
Collapse
|
4
|
Kim KM, Hussein UK, Park SH, Moon YJ, Zhang Z, Ahmed AG, Ahn AR, Park HS, Kim JR, Jang KY. Expression of IL4Rα and IL13Rα1 are associated with poor prognosis of soft-tissue sarcoma of the extremities, superficial trunk, and retroperitoneum. Diagn Pathol 2021; 16:2. [PMID: 33419470 PMCID: PMC7796579 DOI: 10.1186/s13000-020-01066-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Accepted: 12/29/2020] [Indexed: 02/08/2023] Open
Abstract
Background IL4Rα and IL13Rα1 are constituents of the type II IL4 receptor. Recently, IL4Rα and IL13Rα1 were reported to have roles in cancer progression and suggested as potential prognostic markers. However, studies on IL4Rα and IL13Rα1 in soft-tissue sarcomas have been limited. Methods This study investigated the immunohistochemical expression of IL4Rα and IL13Rα1 in 89 soft-tissue sarcomas of the extremities, superficial trunk, and retroperitoneum. Immunohistochemical staining for IL4Rα and IL13Rα1 were scored according to a combination of staining intensity and staining area in tissue microarray samples. Positivity for the immunohistochemical expression of IL4Rα and IL13Rα1 were determined using receiver operating curve analysis. Statistical analysis was performed using regression analysis and a chi-square test. Results In human soft-tissue sarcomas, immunohistochemical expression of IL4Rα was significantly associated with IL13Rα1 expression. Nuclear and cytoplasmic expression of IL4Rα and IL13Rα1 were significantly associated with shorter survival of soft-tissue sarcoma patients in univariate analysis. Multivariate analysis indicated that nuclear expression of IL4Rα and IL13Rα1 were independent indicators of shorter overall survival (IL4Rα; p = 0.002, IL13Rα1; p = 0.016) and relapse-free survival (IL4Rα; p = 0.022, IL13Rα1; p < 0.001) of soft-tissue sarcoma patients. Moreover, the co-expression pattern of nuclear IL4Rα and IL13Rα1 was an independent indicator of shorter survival of soft-tissue sarcoma patients (overall survival; overall p < 0.001, relapse-free survival; overall p < 0.001). Conclusions This study suggests IL4Rα and IL13Rα1 are associated with the progression of soft-tissue sarcoma, and the expression of IL4Rα and IL13Rα1 might be novel prognostic indicators of soft-tissue sarcoma patients.
Collapse
Affiliation(s)
- Kyoung Min Kim
- Department of Pathology, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea.,Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical, Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea
| | - Usama Khamis Hussein
- Department of Pathology, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea.,Faculty of Science, Beni-Suef University, Beni-Suef, Egypt
| | - See-Hyoung Park
- Department of Bio and Chemical Engineering, Hongik University, Sejong, Republic of Korea
| | - Young Jae Moon
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical, Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.,Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Zhongkai Zhang
- Department of Orthopedic Surgery, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea
| | - Asmaa Gamal Ahmed
- Department of Pathology, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea.,Faculty of Postgraduate Studies and Advanced Sciences, Beni-Suef University, Beni-Suef, Egypt
| | - Ae-Ri Ahn
- Department of Pathology, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea.,Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical, Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea
| | - Ho Sung Park
- Department of Pathology, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea.,Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical, Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea
| | - Jung Ryul Kim
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical, Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea. .,Department of Orthopedic Surgery, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea.
| | - Kyu Yun Jang
- Department of Pathology, Jeonbuk National University Medical School, 567 Baekje-daero, Dukjin-gu, Jeonju, 54896, Republic of Korea. .,Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical, Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.
| |
Collapse
|
5
|
Zhang Z, Ha SH, Moon YJ, Hussein UK, Song Y, Kim KM, Park SH, Park HS, Park BH, Ahn AR, Lee SA, Ahn SJ, Kim JR, Jang KY. Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma. J Exp Clin Cancer Res 2020; 39:247. [PMID: 33198792 PMCID: PMC7670730 DOI: 10.1186/s13046-020-01759-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Accepted: 11/01/2020] [Indexed: 12/15/2022]
Abstract
Background SIRT6 has diverse roles in cells, and the role of SIRT6 in tumorigenesis is controversial. Considering the role of SIRT6 as an inducer of DNA damage repair, it might be involved in resistance to anti-cancer therapy. Methods We evaluated the prognostic significance of SIRT6 in 37 osteosarcomas and investigated the therapeutic efficacy of SIRT6 on the anticancer effects of doxorubicin, olaparib, and ATM inhibitor. Results Immunohistochemical expression of SIRT6 was significantly associated with shorter overall survival and relapse-free survival of osteosarcoma patients, especially in patients who received adjuvant chemotherapy. In U2OS and KHOS/NP osteosarcoma cells, knock-down of SIRT6 significantly potentiated apoptotic effects of doxorubicin and SIRT6 overexpression induced resistance to doxorubicin. Moreover, SIRT6 induced the DNA damage repair pathway and SIRT6-mediated resistance to doxorubicin was attenuated by blocking the DNA damage repair pathway with olaparib and ATM inhibitor. Conclusions This study suggests that suppression of SIRT6 in combination with doxorubicin might be an effective modality in the treatment of osteosarcoma patients, especially for osteosarcomas with shorter survival with high expression of SIRT6.
Collapse
Affiliation(s)
- Zhongkai Zhang
- Department of Orthopedic Surgery, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Sang Hoon Ha
- Division of Biotechnology, Jeonbuk National University, Iksan, Republic of Korea
| | - Young Jae Moon
- Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, Jeonju, Republic of Korea.,Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea
| | - Usama Khamis Hussein
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.,Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea.,Faculty of Science, Beni-Suef University, Beni-Suef, Egypt
| | - Yiping Song
- Department of Orthopedic Surgery, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Kyoung Min Kim
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.,Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - See-Hyoung Park
- Department of Bio and Chemical Engineering, Hongik University, Sejong, Republic of Korea
| | - Ho Sung Park
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.,Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Byung-Hyun Park
- Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Ae-Ri Ahn
- Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Sang-A Lee
- Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Su Jin Ahn
- Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, Jeonju, Republic of Korea
| | - Jung Ryul Kim
- Department of Orthopedic Surgery, Jeonbuk National University Medical School, Jeonju, Republic of Korea. .,Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.
| | - Kyu Yun Jang
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea. .,Department of Pathology, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
| |
Collapse
|